STOCK TITAN

Cellectis Stock Price, News & Analysis

CLLS Nasdaq

Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.

Cellectis S.A. (NASDAQ: CLLS) is a clinical-stage biopharmaceutical leader developing groundbreaking allogeneic CAR-T therapies through precision gene-editing technologies. This page provides investors and industry professionals with essential updates on the company’s clinical trials, regulatory milestones, and strategic developments.

Access real-time announcements including FDA submissions, partnership agreements, and research breakthroughs. Our curated collection features press releases on TALEN®-engineered therapies, hematopoietic stem cell advancements, and financial results – all critical for evaluating this innovator in off-the-shelf cancer treatments.

Key updates cover three focus areas: clinical trial phases for UCART candidates, intellectual property developments, and collaborative research initiatives. Bookmark this page to monitor progress in scalable cancer immunotherapies and maintain informed perspectives on Cellectis’ position within the competitive gene-editing landscape.

Rhea-AI Summary

Cellectis reported its share and voting rights data for January 31, 2023. The company has a total of 45,675,968 shares in capital and 51,743,288 voting rights. Cellectis specializes in gene-editing technology, focusing on innovative CAR-T therapies for cancer treatment and using its TALEN® platform to develop various therapies. Based in Paris, with operations in New York and Raleigh, Cellectis aims to address unmet medical needs through its leading-edge approaches in cell and gene therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.43%
Tags
none
-
Rhea-AI Summary

Cellectis announced the initial closing of an underwritten global offering on February 7, 2023, involving 8,800,000 American Depositary Shares (ADSs) at an offering price of $2.50 each, raising gross proceeds of approximately $24.77 million. Additionally, underwriters exercised an option for 1,107,800 additional ADSs, expected to close on February 8, 2023. The net proceeds will primarily support the clinical development of its UCART therapies. Following these transactions, Cellectis anticipates sufficient funds to operate until Q2 2024. The offering was based on the average trading price of the ordinary shares, minus a discount.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.46%
Tags
none
-
Rhea-AI Summary

Cellectis S.A. (NASDAQ: CLLS) has announced a global offering of 8,800,000 American Depositary Shares (ADS) at a public price of $2.50 per ADS, initiated on February 2, 2023. The offering is set to close around February 7, 2023, pending usual closing conditions. Major shareholders, including Bpifrance and Baillie Gifford, will receive a significant portion of the offering. The company's ordinary shares were temporarily suspended on Euronext Growth on February 3, with trading expected to resume later that day. As a biotechnology entity, Cellectis focuses on gene-editing technologies to develop innovative therapies for various diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
Rhea-AI Summary

Cellectis S.A. has launched an underwritten global offering of 8,800,000 American Depositary Shares (ADS) at $2.50 each, aimed at raising approximately $20.2 million post-expenses. The proceeds are intended for clinical development of UCART therapies and general corporate purposes. The offering, scheduled to close on February 7, 2023, will lead to a dilution of approximately 16.2% of existing shares. The offered ADSs will commence trading on the Nasdaq Global Market. Jefferies and Barclays are the joint book-running managers for the offering, which is backed by a 30-day option for underwriters to purchase additional shares. These steps follow Cellectis' strategy to fund its cell and gene therapy advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
-
Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company focused on gene-editing therapies, has launched a global offering of $22 million in American Depositary Shares (ADS). Each ADS represents one ordinary share, with a nominal value of €0.05. The offering includes a public offering in the U.S. and a private placement for qualified investors in other countries. Proceeds will support the clinical development of several product candidates and general corporate purposes. The offering size and price will be determined through an accelerated bookbuilding process. Cellectis has been granted the option for underwriters to purchase an additional 15% of the offering.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.01%
Tags
none
-
Rhea-AI Summary

Cellectis (NASDAQ: CLLS) announced an amendment to the financial terms of a $20 million convertible note with Cytovia Therapeutics. The amended note allows for automatic conversion into Cytovia's common stock during specific fundamental transactions and also grants Cellectis conversion options upon financing or company sale. Key changes include an increase in the interest rate to 10% per annum, a requirement for 50% repayment by April 30, 2023, and an extension of the final maturity date to June 30, 2023. Cellectis leverages its gene-editing platform for innovative cell and gene therapies targeting difficult medical conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.46%
Tags
none
Rhea-AI Summary

Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) announced the merger of Calyxt (NASDAQ: CLXT) and Cibus Global. The all-stock transaction will merge these agriculture-based gene editing companies, combining their resources for trait development and plant breeding. Cellectis holds a 49.1% equity interest in Calyxt, expected to decrease to approximately 2.5% post-merger. The merger requires approvals from Calyxt’s stockholders and Cibus’ members, along with necessary regulatory approvals, with closing anticipated in Q2 2023. The merger aims to leverage the strengths of both companies in gene editing technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
-
Rhea-AI Summary

The merger between Calyxt and Cibus aims to create a leading entity in precision gene editing and sustainable agriculture. Under the all-stock deal, Calyxt shareholders will retain approximately 5% of the new company, which will operate under the name Cibus Inc. Key applications include enhancing productivity traits in seeds and developing renewable low-carbon ingredients. The merger supports a strong collaboration pipeline with major seed companies, with three productivity traits expected to launch in early 2023. Both companies anticipate significant regulatory developments that could enhance market opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.98%
Tags
-
Rhea-AI Summary

Cellectis has announced its intention to conduct an at-the-market offering (ATM) of up to $60 million in American Depositary Shares (ADS) as of January 4, 2023. This program is set to run until July 6, 2025, unless terminated earlier. The funds raised will primarily support the clinical development of its gene therapies, including UCART 123 and others. The potential dilution for existing shareholders is estimated at approximately 23.04%. Jefferies LLC will act as the sales agent, with shares issued without preferential rights for existing shareholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
none
Rhea-AI Summary

Cellectis (Nasdaq: CLLS) has entered into a collaboration with Primera Therapeutics, facilitated by Mayflower Bioventures. The partnership aims to develop gene editing therapies targeting mitochondrial diseases, which currently lack effective treatments. Primera will leverage its innovations from the Mayo Clinic to address mutations in mitochondrial DNA. Cellectis will acquire a 19% stake in Primera and may earn up to $750 million in milestone payments as well as royalties. This collaboration emphasizes Cellectis’ commitment to addressing unmet medical needs through gene editing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.69%
Tags
none

FAQ

What is the current stock price of Cellectis (CLLS)?

The current stock price of Cellectis (CLLS) is $1.58 as of July 3, 2025.

What is the market cap of Cellectis (CLLS)?

The market cap of Cellectis (CLLS) is approximately 149.3M.
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

149.26M
69.50M
3.87%
20.71%
0.24%
Biotechnology
Healthcare
Link
France
Paris